El-Nile Co. for Pharmaceuticals & Chemical Industries

As of March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries carries a market capitalization of 4.80B, placing it among publicly traded companies globally. Its enterprise value stands at 6.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries has 50.00M shares outstanding.

As of March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries trades at a trailing price-to-earnings ratio of 18.98. The price-to-sales ratio is 2.04, and the price-to-book ratio stands at 4.35.

These figures are as of March 31, 2026. The EV/Sales ratio of 2.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.08B versus a market cap of 4.80B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries maintains a current ratio of 1.13, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries recorded 70.28M in income tax expense. That works out to an effective tax rate of 22.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 310.85M, leaving 240.13M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries's stock has gained approximately 96.04% over the past 52 weeks. The 50-day moving average sits at 328.57, while the 200-day moving average is 188.47.

Over the twelve months ended March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries generated 2.24B in revenue and converted that into 240.13M in net income, yielding earnings per share of 5.84.

As of March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries holds 21.20M in cash and equivalents against 1.31B in total debt, resulting in a net debt position of 1.29B. Total book value stands at 1.10B, with working capital of 190.52M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries posted a gross margin of 31.39, reflecting its pricing power and cost economics.

Over the twelve months ended March 31, 2026, El-Nile Co. for Pharmaceuticals & Chemical Industries paid dividends of -1.21 per share. The dividend payout ratio of -20.65 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -2.50, meaning El-Nile Co. for Pharmaceuticals & Chemical Industries raised more capital through share issuance and new debt than it returned via dividends and buybacks.

El-Nile Co. for Pharmaceuticals & Chemical Industries's most recent stock split took place on August 12, 2025 with a 862:1295 split ratio.